Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 2

A Study of Surgery and Radiotherapy in People With Breast Cancer

NCT07053085 · View on ClinicalTrials.gov ↗

Study Summary

The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. The researchers will also study the side effects of the study treatment.

Interventions

  • RADIATION Radiotherapy
  • PROCEDURE Lumpectomy or mastectomy
  • DRUG Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs

Study Locations (7)

New York

  • Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities ) — Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities) — Harrison
  • Memorial Sloan Kettering Cancer Center (All protocol activites) — New York
  • Memorial Sloan Kettering Nassau (Limited protocol activities) — Rockville Centre

New Jersey

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities) — Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities) — Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities) — Montvale

Trial Details

FieldValue
Enrollment Target 162 participants
Start Date 2025-09-17
Est. Completion 2029-09-17
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

2,280 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07053085

The ClinicalTrials.gov registry entry for NCT07053085 describes a study currently listed as recruiting. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 2,280 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 2 conditions, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 3 interventions — of which Radiotherapy is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07053085 reports 7 study locations spanning 2 distinct geographic areas — top geographies include New York, New Jersey. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07053085 about?

NCT07053085 is a clinical study titled "A Study of Surgery and Radiotherapy in People With Breast Cancer". The researchers are doing this study to see if the combination of surgery, locoregional radiation therapy, SBRT (stereotactic body radiation therapy), and the usual approach is more effective in treating oligometastatic HER2-positive breast cancer than the usual approach alone. The researchers will ...

What is the current status of trial NCT07053085?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 162 participants. The study started on 2025-09-17. Estimated completion is 2029-09-17.

What conditions does trial NCT07053085 study?

This clinical trial studies the following conditions: Metastatic Breast Cancer, HER2-positive Breast Cancer. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07053085?

The interventions under investigation include: Radiotherapy (RADIATION), Lumpectomy or mastectomy (PROCEDURE), Trastuzumab, Pertuzumab, Paclitaxel, or a combination of these drugs (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07053085?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 2,280 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07053085 being conducted?

This trial has 7 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial